The control room of Euronext, a company that manages the Paris Stock Exchange (AFP / Archives / ERIC PIERMONT)
The Paris Bourse ended down 0.82% on Monday, weighed down by the progression of the Omicron variant in Europe and by the prospect of new restrictive measures before or after the end of year holidays.
The CAC 40 index lost 56.53 points to 6,870.10 points. On Friday, it had fallen 1.12%.
The Parisian quotation started the session sharply down, losing more than 2.5% in the first exchanges. She recovered a bit throughout the day.
The fall of the morning is “exaggerated” compared to the information reached to the ears of the investors, estimates Andréa Tuéni, of Saxo Bank.
Two weeks from the end of the year, and after a series of decisions by central banks last week, “the market operates according to the announcements of the day, refocuses on one-off events,” he said.
The tone of the health news had something to worry about market operators, with new restrictive measures in several European countries, including confinement in the Netherlands, or calls to be taken, for example in Germany.
The World Economic Forum, which was scheduled to meet January 17-21 in Davos, Switzerland, “is postponed” because of the spread of the Omicron variant.
The Parisian market has however regained a little consistency, remaining solid even after the opening of the American markets sharply (-1.75% for the Dow Jones shortly before the French close), while the president’s massive spending plan American Joe Biden suffered a halt after Democratic Senator Joe Manchin refused to vote for him.
Vaccines came to the aid of the Parisian market. In the morning, the results of a clinical study showed that a booster of Moderna’s anti-Covid vaccine made with a full dose, against a half-dose currently, increased its effectiveness even more against the Omicron variant.
In the afternoon, the European Commission authorized the use in the EU of the anti-Covid vaccine from the American Novavax, in the wake of the green light given by the European Medicines Agency (EMA). This makes it the fifth vaccine approved in Europe.
BNP Paribas sells its American subsidiary Bank of the West
BNP Paribas finished up 0.45% to 56.42 euros after announcing the conclusion of an agreement with the Bank of Montreal (BMO) to sell it its American subsidiary Bank of the West, for an amount of 16, $ 3 billion.
Biotechs benefit from the context, not Ipsen
The French giant of analysis laboratories Eurofins Scientific, whose activity is driven by Covid-19 and the screening tests it generates, finished at the top of the CAC 40 (+ 2.59% to 109.24 euros ). Sanofi ended in equilibrium (+ 0.01% to 86.90 euros).
On the SBF 120, Genfit (+ 7.40% to 4.53 euros), prolonged the euphoria of Friday (+ 40%), after the announcement of the taking of an 8% stake in the Ipsen laboratory.
Ipsen, which had fallen 8% Friday, plunged 7.36% to 79.54 euros, after the acceptance by the American administration of a rival treatment of its Somatuline, by the Indian Cipla. The laboratory assured during the day that this did not change anything in its medium-term forecasts, in 2024.
© 2021 AFP
Did you like this article ? Share it with your friends with the buttons below.
